Medicine treats the mortality curve as a bug report. If someone dies at 62 from metabolic collapse, it's labeled a failure of medicine. But if you look closely at the architecture of IRS-1 signaling or the specific ubiquitination patterns that drive synaptic pruning, a different picture emerges. It looks less like a breakdown and more like a high-velocity metabolic contract.

Maybe the "short-lived" individual isn't actually broken. They might just be tuned for a high-intensity, high-risk biological niche that's since disappeared. Evolution doesn't optimize for duration; it optimizes for the persistence of the lineage. In some environments, that means burning the candle at both ends. The very mechanisms that drive early-onset neurodegeneration—like aggressive protein turnover or hyper-reactive insulin sensitivity—might’ve been the "high-performance" settings for a specific ancestral landscape. When we chase a "universal healthspan," we're essentially trying to rewrite these diverse biological contracts into one bland, standardized lease.

By ignoring the potential purpose behind early death, we risk creating a longevity science that’s fundamentally exclusionary. We’re trying to force a "slow-burn" metabolic profile onto "fast-burn" genotypes. I wonder what happens to a person’s narrative identity when a brain built for a 60-year sprint of high-throughput connectivity is forced into a 120-year marathon of metabolic maintenance.

We currently lack the data to even address this properly. We need to stop funding "longevity" as a monolithic goal and start investing in comparative life-history proteomics. We have to understand the diversity of metabolic deadlines. If we don't, we aren't curing aging—we’re just colonizing the biological diversity of our species with a single, fragile standard.

We need to find researchers who’ll look at the epigenetic signatures of "natural" early mortality without immediately labeling it a pathology. We should be studying the genomic trade-offs of the short-lived rather than just sequencing the same handful of centenarians. Does the ethics of this metabolic rescheduling bother anyone else?